Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(2 sites)
France
Institut Gustave Roussy, Paris Netherlands
Princess Máxima Center for Pediatric Oncology, Utrecht, Utrecht Last updated December 2025